Reply to X. Armoiry et al.
[Systematic review and network meta-analysis of treatment outcomes for multiple myeloma. J Clin Oncol 35:2975-2976, 2017]
We would like to thank Armoiry et al1 for investing the time and effort to further advance our research.We carefully considered their solution to our assumption regarding the equal relative effectiveness of bortezomib (Bor) versus dexamethasone (Dex) and bortezomib plus dexamethasone (BorDex) versus Dex. [...]
|Sponsor||Supported by Grant No. 152001020 from ZonMw, the Netherlands Organisation for Health Research and Development.|
|Persistent URL||dx.doi.org/10.1200/JCO.2017.73.7569, hdl.handle.net/1765/101935|
|Journal||Journal of Clinical Oncology|
van Beurden-Tan, C.H.Y, Franken, M.G, Blommestein, H.M, Uyl-de Groot, C.A, & Sonneveld, P. (2017). Reply to X. Armoiry et al. Journal of Clinical Oncology, 35(25), 2976–2977. doi:10.1200/JCO.2017.73.7569